CG ONCOLOGY INC

CG Oncology stock dips 10.25% this month, now at $62.17 with a $5.5B cap. Find out why investors are cautious amid its bladder‑cancer drug focus.

CG Oncology (CGON) climbs 3.29% as insiders exercise options and sales, pushing the stock toward its 52‑week high and near its 200‑day SMA.

CG Oncology (CGON) trading recap: see 24‑hour price, market cap, peer comparison, and a focus on bladder‑cancer therapy. Update on Nasdaq listing.